-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SqYRGiYy2t8vWNGkDPpoJgwFIwQQDEwNtK9JNW6sm5/m1Wx2yZ1KHmUIb13LSWFe XHsytZCAZO+DTeMBrzVGUA== 0000947871-04-000127.txt : 20040202 0000947871-04-000127.hdr.sgml : 20040202 20040202154710 ACCESSION NUMBER: 0000947871-04-000127 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-95805 FILM NUMBER: 04559216 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2124496202 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_012704-pharmaceutical.txt PROSPECTUS SUPPLEMENT - PHARMACEUTICAL PROSPECTUS SUPPLEMENT Filed Pursuant to Rule No. 424(b)(3) (To Prospectus dated July 7, 2003) REGISTRATION NO. 333-92161 333-95805 [PHARMACEUTICAL HOLDRS LOGO] 1,000,000,000 Depositary Receipts Pharmaceutical HOLDRS (SM) Trust This prospectus supplement supplements information contained in the prospectus dated July 7, 2003 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS (SM) Trust. The share amounts specified in the table on page 11 of the base prospectus shall be replaced with the following:
Share Primary Name of Company Ticker Amounts Trading Market ------------------------------------ ------ ------- -------------- Abbott Laboratories ABT 14 NYSE Allergan, Inc. AGN 1 NYSE Andrx Corporation-Andrx Group ADRX 2 NASDAQ Advanced Medical Optics, Inc. AVO 0.222222 NYSE Biovail Corporation BVF 4 NYSE Bristol-Myers Squibb Company BMY 18 NYSE Eli Lilly & Company LLY 10 NYSE Forest Laboratories, Inc. FRX 4 NYSE IVAX Corporation IVX 1.875 AMEX Johnson & Johnson JNJ 26 NYSE King Pharmaceuticals, Inc. KG 4.25 NYSE Medco Health Solutions MHS 2.6532 NYSE Merck & Co., Inc. MRK 22 NYSE Mylan Laboratories, Inc.(1) MYL 2.25 NYSE Pfizer Inc. PFE 58 NYSE Schering-Plough Corporation SGP 14 NYSE Valeant Pharmaceuticals(2) VRX 1 NYSE Watson Pharmaceuticals, Inc. WPI 1 NYSE Wyeth WYE 12 NYSE Zimmer Holdings, Inc. ZMH 1.8 NYSE
--------------- (1) Mylan Laboratories Inc. announced a 3-for-2 stock split on its common stock payable to shareholders of record as of September 30, 2003. As of October 15, 2003 the share amount of Mylan Laboratories Inc. represented by a round lot of 100 Pharmaceutical HOLDRS was 2.25. (2) As of November 14, 2003, ICN Pharmaceuticals Inc., an underlying constituent of Pharmaceutical HOLDRS, changed its name to Valeant Pharmaceuticals. As of November 14, 2003, 1 share of Valeant Pharmaceuticals was included in each round-lot of 100 Pharmaceutical HOLDRS. The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions. The date of this prospectus supplement is December 31, 2003. -----END PRIVACY-ENHANCED MESSAGE-----